In general, these findings argue strongly against the idea that the effect of expanding coverage on utilization can be deduced simply from the reduction in patient cost sharing.
Genomic knowledge, of humans and other species, will transform medicine by introducing side-effect-free drugs that work first time, expanding the range of diseases that are treatable and refining diagnosis.